WO2012021475A3 - ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF Download PDFInfo
- Publication number
- WO2012021475A3 WO2012021475A3 PCT/US2011/047002 US2011047002W WO2012021475A3 WO 2012021475 A3 WO2012021475 A3 WO 2012021475A3 US 2011047002 W US2011047002 W US 2011047002W WO 2012021475 A3 WO2012021475 A3 WO 2012021475A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amyloid beta
- beta peptide
- peptide antibodies
- n3pglu amyloid
- n3pglu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Abstract
Anti-N3pGlu amyloid beta antibodies useful in the treatment of Alzheimer's Disease are provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37301610P | 2010-08-12 | 2010-08-12 | |
| US61/373,016 | 2010-08-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012021475A2 WO2012021475A2 (en) | 2012-02-16 |
| WO2012021475A3 true WO2012021475A3 (en) | 2012-07-05 |
Family
ID=45568152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/047002 WO2012021475A2 (en) | 2010-08-12 | 2011-08-09 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012021475A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170004B1 (en) * | 2016-01-15 | 2022-09-15 | Lilly Co Eli | ANTl-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| TW201740954A (en) * | 2016-03-16 | 2017-12-01 | 美國禮來大藥廠 | Combination therapy |
| TWI798751B (en) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| CN109562167A (en) * | 2016-08-09 | 2019-04-02 | 伊莱利利公司 | Combination therapy |
| TW201827467A (en) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | Antibodies to pyroglutamate amyloid-[beta] and uses thereof |
| JOP20190247A1 (en) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| EA202192606A1 (en) | 2019-03-26 | 2022-01-24 | Янссен Фармацевтика Нв | ANTIBODIES TO PYROGLUTAMATE-AMYLOID AND THEIR APPLICATIONS |
| MX2023000949A (en) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anti-abeta antibodies. |
| TW202243690A (en) * | 2021-01-11 | 2022-11-16 | 美商美國禮來大藥廠 | Anti-n3pglu amyloid beta antibodies and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| US20080050370A1 (en) * | 2006-03-17 | 2008-02-28 | Scott Glaser | Stabilized polypeptide compositions |
| US20100021478A1 (en) * | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
-
2011
- 2011-08-09 WO PCT/US2011/047002 patent/WO2012021475A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| US20080050370A1 (en) * | 2006-03-17 | 2008-02-28 | Scott Glaser | Stabilized polypeptide compositions |
| US20100021478A1 (en) * | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012021475A2 (en) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012021475A3 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| BRPI1012853A2 (en) | protofibrillar beta-amyloid peptide-specific humanized antibodies | |
| HRP20180230T8 (en) | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies | |
| IL254157B (en) | 14-3-3eta antibodies and uses thereof for the diagnosis and treatment of arthritis | |
| UA107600C2 (en) | ANTIBODY AGAINST N3pGlu BETA-AMYLOID PAPIDE AND ITS APPLICATION | |
| CA2883095C (en) | Antibody and protein formulations | |
| IL231201B (en) | Isolated antibody for therapy and diagnosis of tau-mediated pathology in alzheimer's disease | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| EP2558493A4 (en) | Antibodies for the treatment of clostridium difficile-associated infection and disease | |
| LT2498620T (en) | Protein concentrates and isolates, and processes for the production thereof | |
| IL232325A0 (en) | 18-methyl-6'7-methylene-3-oxo-17-pregn-4-ene-21,17b-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis | |
| EP2519234A4 (en) | Anaplerotic therapy for alzheimer's disease and the aging brain | |
| WO2013059530A3 (en) | Peptidomimetic macrocycles | |
| SG179095A1 (en) | Novel assay for the detection of amyloid beta peptides | |
| AP2957A (en) | New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs | |
| EP2651965A4 (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
| IL210364A (en) | Cyclic peptide analogue of the ß-amyloid peptide and uses thereof in the treatment or diagnosis of neurodegenerative diseases or conditions | |
| WO2011072257A3 (en) | Amyloid binding agents | |
| EP2182978A4 (en) | Tissue kallikrein for the treatment of diseases associated with amyloid protein | |
| EP3558340A4 (en) | Methods of using gm6 in diagnosing and treating alzheimer's disease | |
| EP3086846A4 (en) | Diagnosing and treating alzheimer's disease | |
| HK1151241A1 (en) | Enhancement of the efficacy of therapeutic proteins | |
| BR112012006005A2 (en) | "peptides in the treatment of oxidative stress disorder" | |
| GB2458868B (en) | Fluphenazine based combination for use in the treatment of protein aggregation diseases | |
| GB201220630D0 (en) | Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11816897 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11816897 Country of ref document: EP Kind code of ref document: A2 |